
- /
- Supported exchanges
- / US
- / BCAX.NASDAQ
Bicara Therapeutics Inc. Common Stock (BCAX NASDAQ) stock market data APIs
Bicara Therapeutics Inc. Common Stock Financial Data Overview
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Bicara Therapeutics Inc. Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Bicara Therapeutics Inc. Common Stock data using free add-ons & libraries
Get Bicara Therapeutics Inc. Common Stock Fundamental Data
Bicara Therapeutics Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -121 003 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.5367
Get Bicara Therapeutics Inc. Common Stock End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bicara Therapeutics Inc. Common Stock News

Bicara Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ...


H.C. Wainwright lowers Bicara Therapeutics stock price target to $40 on expenses
Investing.com - H.C. Wainwright reduced its price target on Bicara Therapeutics Inc (NASDAQ:BCAX) to $40.00 from $41.00 on Friday, while maintaining a Buy rating on the stock. The $635 million marke...

Summit draws Neutral view on risk/reward setup as Piper initiates biotech cancer names
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Piper Sandler launched the coverage of a raft of cancer-focused biotechs with bullish views on Monday while issuing a Neutral recommendation on ...

Piper Sandler initiates coverage of oncology companies
[Wall Street New York stock exchange stock market] alexsl Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: _CG Oncology (NASDAQ:CGON [https://se...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.